| Company Name: |
TOSUN PHARM |
| Tel: |
020-66392521-118 18922260391 |
| Email: |
3004261881@qq.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Basic information |
| Product Name: | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate | | Synonyms: | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate;Beraprost sodium (Relative stereochemistry);Beraprost Impurity 10 Sodium Salt;Beraprost impurity 27;Beraprost Sodium (Mixture of Diastereomers);Bera st Sodium Salt(Mixture of Diastereomers) | | CAS: | 496807-11-5 | | MF: | C24H31NaO5 | | MW: | 422.5 | | EINECS: | | | Product Categories: | | | Mol File: | 496807-11-5.mol | ![sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Structure](CAS/20180601/GIF/496807-11-5.gif) |
| | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (594.57 mM) | | form | Solid | | color | White to light yellow |
| | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Usage And Synthesis |
| Biological Activity | Beraprost sodium, a prostacyclin analog, is a stable and orally active PGI2 prodrug. It is an effective vasodilator, which has the potential to study pulmonary hypertension by dilating renal blood vessels and improving microcirculation. | | in vitro | Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions. < /b> | | in vivo | Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis . | Animal Model: | 6-8-week-old C57Bl/6J Male Mice | | Dosage: | 0.6 mg/kg | | Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days | | Result: < /td> | Mitigated the development of renal interstitial fibrosis. | | | target | prodrug of PGI2; Vasodilator | | storage | Store at -20°C |
| | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Preparation Products And Raw materials |
|